---
title: "12 Health Care Stocks Moving In Friday's Intraday Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303785884.md"
description: "During Friday's intraday session, several healthcare stocks experienced significant volatility. Gainers included CareDx (+22.2%), Jin Medical (+20.43%), and Regeneron Pharmaceuticals (+11.14%), with price movements often coinciding with Q3 earnings reports. Conversely, major losers featured Acumen Pharmaceuticals (-88.9%), ProMIS Neurosciences (-64.08%), and Pelthos Therapeutics (-40.45%). The session highlighted sharp reactions to recent financial disclosures among these listed companies."
datetime: "2026-10-30T17:05:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303785884.md)
  - [en](https://longbridge.com/en/news/303785884.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303785884.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Friday's Intraday Session

### Gainers

-   **CareDx** (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.
-   **Jin Medical International** (NASDAQ:ZJYL) stock rose 20.43% to $2.24. The company's market cap stands at $14.5 million.
-   **EUDA Health Holdings** (NASDAQ:EUDA) shares rose 13.25% to $17.55. The market value of their outstanding shares is at $46.4 million.
-   **Profound Medical** (NASDAQ:PROF) shares increased by 11.6% to $6.54. The company's market cap stands at $214.1 million.
-   **Regeneron Pharmaceuticals** (NASDAQ:REGN) shares increased by 11.14% to $910.0. The company's market cap stands at $84.2 billion. As per the news, the Q3 earnings report came out today.
-   **BeyondSpring** (NASDAQ:BYSI) stock rose 10.31% to $0.57. The market value of their outstanding shares is at $21.2 million.

### Losers

-   **Acumen Pharmaceuticals** (NASDAQ:ABOS) shares fell 88.9% to $0.25 during Friday's regular session. The company's market cap stands at $165.6 million. The company's, Q3 earnings came out 4 days ago.
-   **ProMIS Neurosciences** (NASDAQ:PMN) shares decreased by 64.08% to $3.98. The company's market cap stands at $99.3 million.
-   **Pelthos Therapeutics** (AMEX:PTHS) stock declined by 40.45% to $9.85. The company's market cap stands at $63.3 million.
-   **Alphatec Holdings** (NASDAQ:ATEC) stock decreased by 38.53% to $6.99. The market value of their outstanding shares is at $1.7 billion. As per the news, the Q3 earnings report came out yesterday.
-   **Azora Therapeutics** (NASDAQ:AZR) shares declined by 34.43% to $3.2. The market value of their outstanding shares is at $12.8 million.
-   **Pomdoctor** (NASDAQ:POM) stock decreased by 31.66% to $1.36. The company's market cap stands at $5.5 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ABOS.US](https://longbridge.com/en/quote/ABOS.US.md)
- [ATEC.US](https://longbridge.com/en/quote/ATEC.US.md)
- [BYSI.US](https://longbridge.com/en/quote/BYSI.US.md)
- [CDNA.US](https://longbridge.com/en/quote/CDNA.US.md)
- [EUDA.US](https://longbridge.com/en/quote/EUDA.US.md)
- [POM.US](https://longbridge.com/en/quote/POM.US.md)
- [PROF.US](https://longbridge.com/en/quote/PROF.US.md)
- [PTHS.US](https://longbridge.com/en/quote/PTHS.US.md)
- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [ZJYL.US](https://longbridge.com/en/quote/ZJYL.US.md)
- [PMN.US](https://longbridge.com/en/quote/PMN.US.md)
- [AZR.US](https://longbridge.com/en/quote/AZR.US.md)

## Related News & Research

- [Did Alphatec's Fall Catch You Out? What Investors Missed](https://longbridge.com/en/news/303089224.md)
- [ATEC Q3 2026 Earnings: Biologics Weakness Limits Revenue Growth](https://longbridge.com/en/news/303624186.md)
- [Regeneron hits 52-week high after “standout” Q3](https://longbridge.com/en/news/303793362.md)
- [WestEnd Advisors LLC Buys 8,528 Shares of Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/303375890.md)
- [Regeneron Q3 revenue beats on Dupixent demand](https://longbridge.com/en/news/303730253.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**